Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Interim Results

25 Aug 2015 07:00

RNS Number : 9375W
Ovoca Gold PLC
25 August 2015
 



Ovoca Gold plc ("Ovoca" or the "Company")

 

2015 Interim Results

 

Ovoca is pleased to announce its interim financial statements and report covering the six month period from 1 January 2015 to 30 June 2015.

 

Please click on the following link to view the full Half Year Report:

 

http://www.rns-pdf.londonstockexchange.com/rns/9375W_-2015-8-24.pdf 

 

Highlights:

· Cash and cash equivalents and available for sale financial assets of Euro 19 million as at 30 June 2015.

 

· Total comprehensive profit for the six months period to 30 June 2015 of Euro 0.6 million.

 

· Total finance income in the period amounted to approximately Euro 0.4 million, relating to our holding of Polymetal International plc shares.

 

 

Post period events:

· On 28 April 2015, the Board of Ovoca announced that it purchased 5.800.000 ordinary shares of nominal value €0.125 each in the issued share capital of the Company ("Ordinary Shares") at a price of GBP 6.8p. Ovoca intends to hold these shares as treasury stock. Ovoca now has a total of 81,563,806 Ordinary Shares in issue excluding treasury shares and 6,895,000 Ordinary Shares held in treasury. The purchase was made pursuant to the authority granted by shareholders at an Extraordinary General Meeting of the Company held on 17 October 2014.

 

CEO's Letter

 

Dear shareholders,

 

It is my pleasure to report to you our financials and the results of our work for the first half of 2015.

 

In 2015 the Company continued the search for a JV partner to develop the Stakhanovsky Licence and/or for a potential Buyer of the Company's interest in the Stakhanovsky Licence. Due to unstable geopolitical and market conditions, the decline in commodity prices and devaluation of the Russian national currency, most of the industry players in Russia are very cautious proceeding with JVs and/or acquisitions. Those factors have certainly influenced our efforts, however management hopes that the situation will improve and that the right partner can be found.

 

We have made significant progress with the loan recovery from the LLC Taymura, Ovoca's previous acquisition target, which defaulted on the USD 6.3 million loan in 2014. Ovoca had to pass through a routine litigation process with LLC Taymura and the guarantor and received Court decisions in favor of Ovoca for the full amount of the loan together with the incurred interest from both LLC Taymura and the guarantor. As of today, payables, assets and accounts have been seized by the courts on behalf of Ovoca and the Company has recovered approximately USD 1 million in cash and receivables. Ovoca continues to defend its interest and management believes that it will recover substantially the entire loan sum.

 

As we previously reported, the Company decided to widen its focus in exploration projects and since 2014 started to search for new projects in the oil and gas resource sector in Russia, Canada and US. We continue our ongoing search for new projects.

 

 

Kind regards,

 

Kirill Golovanov, CEO

 

 

 

ENDS

 

 

Enquiries:

 

Ovoca Gold Plc

Kirill Golovanov, CEO

 +7 495 916 6029

 

Davy - NOMAD, ESM Adviser and Broker

John Frain / Daragh O'Reilly +353 1 679 6363

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DOCEASPLASSSEFF
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.